A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol

BACKGROUND: Median survival for patients with glioblastoma is less than a year. Standard treatment consists of surgical debulking if feasible followed by temozolomide chemo-radiotherapy. The immune checkpoint inhibitor ipilimumab targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and has s...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Nicholas F., Ng, Stasya M., Brooks, Claire, Coutts, Tim, Holmes, Jane, Roberts, Corran, Elhussein, Leena, Hoskin, Peter, Maughan, Tim, Blagden, Sarah, Mulholland, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068928/
https://www.ncbi.nlm.nih.gov/pubmed/32164579
http://dx.doi.org/10.1186/s12885-020-6624-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068928/
https://www.ncbi.nlm.nih.gov/pubmed/32164579
http://dx.doi.org/10.1186/s12885-020-6624-y

Ejemplares similares